| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ... Blood, The Journal of the American Society of Hematology 128 (9), 1226-1233, 2016 | 234 | 2016 |
| Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma EK Mai, U Bertsch, J Dürig, C Kunz, M Haenel, IW Blau, M Munder, ... Leukemia 29 (8), 1721-1729, 2015 | 198 | 2015 |
| Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma M Merz, T Hielscher, B Wagner, S Sauer, S Shah, MS Raab, A Jauch, ... Leukemia 28 (9), 1902-1908, 2014 | 131 | 2014 |
| Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo study T Bäuerle, D Komljenovic, M Merz, MR Berger, SL Goodman, W Semmler International journal of cancer 128 (10), 2453-2462, 2011 | 97 | 2011 |
| Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents M Merz, K Neben, MS Raab, S Sauer, G Egerer, M Hundemer, D Hose, ... Annals of oncology 25 (1), 189-195, 2014 | 82 | 2014 |
| Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial M Merz, H Salwender, M Haenel, EK Mai, U Bertsch, C Kunz, T Hielscher, ... haematologica 100 (7), 964, 2015 | 78 | 2015 |
| Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study T Bäuerle, M Merz, D Komljenovic, S Zwick, W Semmler Clinical Cancer Research 16 (12), 3215-3225, 2010 | 63 | 2010 |
| A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, MS Raab, M Hillengass, ... Haematologica 100 (6), 818, 2015 | 57 | 2015 |
| Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases M Merz, D Komljenovic, S Zwick, W Semmler, T Bäuerle European Journal of Cancer 47 (2), 277-286, 2011 | 55 | 2011 |
| Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, M Hillengass, B Wagner, ... European radiology 26, 3939-3948, 2016 | 47 | 2016 |
| Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial H Goldschmidt, EK Mai, J Dürig, C Scheid, KC Weisel, C Kunz, U Bertsch, ... Leukemia 34 (7), 1853-1865, 2020 | 46 | 2020 |
| Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma M Merz, AMA Merz, J Wang, L Wei, Q Hu, N Hutson, C Rondeau, ... Nature communications 13 (1), 807, 2022 | 44 | 2022 |
| Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma M Merz, T Hielscher, A Seckinger, D Hose, EK Mai, MS Raab, ... American journal of hematology 91 (11), E473-E477, 2016 | 43 | 2016 |
| Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma M Merz, J Ritsch, C Kunz, B Wagner, S Sauer, D Hose, T Moehler, ... Clinical Cancer Research 21 (1), 106-112, 2015 | 42 | 2015 |
| Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma T Bochtler, M Merz, T Hielscher, M Granzow, K Hoffmann, A Krämer, ... Blood advances 2 (20), 2607-2618, 2018 | 38 | 2018 |
| Survival of elderly patients with multiple myeloma—Effect of upfront autologous stem cell transplantation M Merz, L Jansen, FA Castro, J Hillengass, H Salwender, K Weisel, ... European Journal of Cancer 62, 1-8, 2016 | 37 | 2016 |
| Cilengitide inhibits metastatic bone colonization in a nude rat model M Bretschi, M Merz, D Komljenovic, MR Berger, W Semmler, T Bäuerle Oncology reports 26 (4), 843-851, 2011 | 37 | 2011 |
| EASIX for prediction of survival in lower-risk myelodysplastic syndromes A Merz, U Germing, G Kobbe, J Kaivers, A Jauch, A Radujkovic, ... Blood Cancer Journal 9 (11), 85, 2019 | 33 | 2019 |
| Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma M Merz, A Jauch, T Hielscher, T Bochtler, SO Schönland, A Seckinger, ... Blood advances 2 (1), 1-9, 2018 | 33 | 2018 |
| Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases M Merz, D Komljenovic, W Semmler, T Bäuerle Investigative radiology 47 (7), 422-429, 2012 | 33 | 2012 |
